Structure-based design, synthesis, and biological evaluation of conformationally restricted novel 2-alkylthio-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as non-nucleoside inhibitors of HIV-1 reverse transcriptase

被引:87
|
作者
Mai, A
Sbardella, G
Artico, M
Ragno, R
Massa, S
Novellino, E
Greco, G
Lavecchia, A
Musiu, C
La Colla, M
Murgioni, C
La Colla, P
Loddo, R
机构
[1] Univ Roma La Sapienza, Dipartimento Studi Farmaceut, Fdn Cenci Bolognetti, Ist Pasteur, I-00185 Rome, Italy
[2] Univ Roma La Sapienza, Dipartimento Studi Chim & Tecnol Sostanze Biologi, I-00185 Rome, Italy
[3] Univ Siena, Dipartimento Farmaco Chim Tecnol, I-53100 Siena, Italy
[4] Univ Naples Federico II, Dipartimento Chim Farmaceut & Tossicol, I-80131 Naples, Italy
[5] Novirio Pharmaceut Inc, Boston, MA USA
[6] Univ Cagliari, Sez Microbiol, Dipartimento Biol Sperimentale, I-09042 Cagliari, Italy
关键词
D O I
10.1021/jm010853h
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
5-Alkyl-2-(alkylthio)-6-(2,6-difluorobenzyl)-3,4-dihydropyrimidin-4(3H)-ones (S-DABOs, 2) have been recently described as a new class of human immunodeficiency virus type 1 (HIV-1) nonnucleoside reverse transcriptase (RT) inhibitors (NNRTIs) active at nanomolar concentrations (Mai, A. et al. J. Med. Chem. 1999, 42, 619-627). In pursuing our lead optimization efforts, we designed novel conformationally restricted S-DABOs, 3, featuring a methyl at the benzylic carbon (Y = Me) and at the pyrimidine 5-position (R = Me). Conformational analyses and docking simulations suggested that the presence of both methyls would significantly reduce conformational flexibility without compromising, in the R enantiomers, the capability of fitting into the RT non-nucleoside binding pocket. To develop structure-activity relationships, we prepared several congeners of type 3 belonging to the thymine (R = Me) and uracil (R = H) series, featuring various 2-alkylthio side chains (X = Me, i-Pr, n-Bu, i-Bu, s-Bu, c-pentyl, and c-hexyl) and aryl moieties different from the 2,6-difluorophenyl (Ar = phenyl, 2,6-dichlorophenyl, 1-naphthyl). Moreover, alpha -ethyl derivatives (Y = Et) were included in the synthetic project in addition to alpha -methyl derivatives (Y = Me). All of the new compounds were evaluated for their cytotoxicity and anti-HIV-1 activity in MT-4 cells, and some of them were assayed against highly purified recombinant wild-type HIV-1 RT using homopolymeric template primers. The results were expressed as CC50 (cytotoxicity), EC50 (anti-HIV-1 activity), SI (selectivity, given by the CC50/EC50 ratio), and IC50 (RT inhibitory activity) values. In the 2,6-difluorobenzylthymine (R = Me) series, methylation of the benzylic carbon improved anti-HIV-1 and RT inhibitory activities together with selectivity. Compound 3w (Ar = 2,6-F-2-Ph, R = Y = Me, X = c-pentyl) turned out the most potent and selective among the S-DABOs reported to date (CC50 > 200 muM, EC50 = 6 nM, IC50 = 5 nM, and SI > 33 333). Assays performed on the pure enantiomer (+)-3w, much more active than (-)-3w, yielded the following results: CC50 > 200 muM, EC50 = 2 nM, IC50 = 8 nM, and SI > 100 000, under conditions wherein MKC-442 was less active and selective (CC50 > 200 muM, EC50 = 30 nM, IC50 = 40 nM, SI > 6666). The 2,6-difluorophenylethylthymines (R = Me) were generally endowed with higher potency compared with the uracil counterparts (R = H). In the 2,6-difluorophenyl series the best and the least performant 2-alkylthio side chains were the 2-c-pentylthio and the 2-methylthio, respectively. When the methyl at the benzylic carbon was replaced by an ethyl, activity was retained or decreased slightly, thus suggesting that the dimensions of the cavity within the RT hosting this substituent would not be compatible with groups larger than ethyl. Aryl moieties different from the 2,6-difluorophenyl (phenyl, 1-naphthyl, 2,6-dichlorophenyl) were generally detrimental to activity, consistent with a favorable electronic effect exerted by the 2,6-fluorines on a putative charge-transfer interaction between the aromatic moieties of the inhibitor and Tyr188.
引用
收藏
页码:2544 / 2554
页数:11
相关论文
共 50 条
  • [41] Synthesis and anti-HIV activity of 1,1,3-trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazines (TTDs):: A new family of HIV-1 specific non-nucleoside reverse transcriptase inhibitors
    Arranz, ME
    Díaz, JA
    Ingate, ST
    Witvrouw, M
    Pannecouque, C
    Balzarini, J
    De Clercq, E
    Vega, S
    BIOORGANIC & MEDICINAL CHEMISTRY, 1999, 7 (12) : 2811 - 2822
  • [42] Synthesis and biological evaluation of novel 2-(substituted phenylaminocarbonylmethylthio)-6-(2,6-dichlorobenzyl)-pyrimidin-4(3H)-ones as potent HIV-1 NNRTIs
    Yu, Mingyan
    Liu, Xinyong
    Li, Zhenyu
    Liu, Shuai
    Pannecouque, Christophe
    De Clercq, Erik
    BIOORGANIC & MEDICINAL CHEMISTRY, 2009, 17 (22) : 7749 - 7754
  • [43] Discovery and SAR of a series of 4,6-diamino-1,3,5-triazin-2-ol as novel non-nucleoside reverse transcriptase inhibitors of HIV-1
    Liu, Bin
    Lee, Younghee
    Zou, Jinming
    Petrassi, H. Michael
    Joseph, Rhoda W.
    Chao, Wenchun
    Michelotti, Enrique L.
    Bukhtiyarova, Marina
    Springman, Eric B.
    Dorsey, Bruce D.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (22) : 6592 - 6596
  • [44] Design, synthesis and anti-HIV evaluation of 5-alkyl-6-(benzo[d][1,3] dioxol-5-alkyl)-2-mercaptopyrimidin-4(3H)-ones as potent HIV-1 NNRTIs
    Li, Yi-Ming
    Luo, Rong-Hua
    Yang, Liu-Meng
    Huang, Si-Ming
    Li, Sui-Yuan
    Zheng, Yu-Gui
    Ni, Dong-Xuan
    Cui, Yi-Man
    Zhang, Xing-Jie
    Li, Xiao-Li
    Zhang, Rui-Han
    Tang, E.
    Zhang, Hong-Bin
    Zheng, Yong-Tang
    He, Yan-Ping
    Xiao, Wei-Lie
    BIOORGANIC CHEMISTRY, 2020, 102
  • [45] Discovery of Novel Amino Acids (Analogues)-Substituted Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: Design, Synthesis, and Biological Evaluation
    Zhuo, Zongji
    Wang, Zhao
    Jing, Lanlan
    Zhang, Tao
    Ge, Anchao
    Zhou, Zhenzhen
    Liu, Ying
    Li, Xin
    De Clercq, Erik
    Pannecouque, Christophe
    Zhan, Peng
    Liu, Xinyong
    Kang, Dongwei
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (16)
  • [46] Design, synthesis and biological evaluation of 3-hydroxyquinazoline-2,4(1H, 3H)-diones as dual inhibitors of HIV-1 reverse transcriptase-associated RNase H and integrase
    Gao, Ping
    Cheng, Xiqiang
    Sun, Lin
    Song, Shu
    Alvarez, Mar
    Luczkowiak, Joanna
    Pannecouque, Christophe
    De Clercq, Erik
    Menendez-Arias, Luis
    Zhan, Peng
    Liu, Xinyong
    BIOORGANIC & MEDICINAL CHEMISTRY, 2019, 27 (17) : 3836 - 3845
  • [47] Nonnucleoside HIV-1 reverse transcriptase inhibitors;: part 3.: Synthesis and antiviral activity of 5-alkyl-2-[(aryl and alkyloxyl-carbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones
    He, YP
    Chen, FN
    Yu, XJ
    Wang, YP
    De Clereq, E
    Balzarini, J
    Pannecouque, C
    BIOORGANIC CHEMISTRY, 2004, 32 (06) : 536 - 548
  • [48] Ligand based 3D-QSAR modelling studies on 2-amino-6-aryl sulfonylbenzonitriles (AASBNs) as non-nucleoside reverse transcriptase inhibitors of HIV-1
    Sapre, Nitin S.
    Jain , Nilanjana
    Gupta, Swagata
    Sapre, Neelima
    RSC ADVANCES, 2013, 3 (26): : 10442 - 10451
  • [49] Synthesis and biological evaluation of a series of2-(((5-akly/aryl-1H-pyrazol-3-yl)methyl)thio)-5-alkyl-6-(cyclohexylmethyl)-pyrimidin-4(3H)-ones as potential HIV-1 inhibitors
    Yumeng Wu
    Chengrun Tang
    Ruomei Rui
    Liumeng Yang
    Wei Ding
    Jiangyuan Wang
    Yiming Li
    Christopher C.Lai
    Yueping Wang
    Ronghua Luo
    Weilie Xiao
    Hongbing Zhang
    Yongtang Zheng
    Yanping He
    ActaPharmaceuticaSinicaB, 2020, 10 (03) : 512 - 528
  • [50] Synthesis and biological evaluation of a series of 2-(((5-akly/aryl-1H-pyrazol-3-yl)methyl)thio)-5-alkyl-6-(cyclohexylmethyl)-pyrimidin-4(3H)-ones as potential HIV-1 inhibitors
    Wu, Yumeng
    Tang, Chengrun
    Rui, Ruomei
    Yang, Liumeng
    Ding, Wei
    Wang, Jiangyuan
    Li, Yiming
    Lai, Christopher C.
    Wang, Yueping
    Luo, Ronghua
    Xiao, Weilie
    Zhang, Hongbing
    Zheng, Yongtang
    He, Yanping
    ACTA PHARMACEUTICA SINICA B, 2020, 10 (03) : 512 - 528